These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 22287028

  • 1. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.
    World J Surg Oncol; 2013 Oct 25; 11():284. PubMed ID: 24160898
    [Abstract] [Full Text] [Related]

  • 3. Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.
    Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.
    Biomed Res Int; 2013 Oct 25; 2013():756302. PubMed ID: 24083241
    [Abstract] [Full Text] [Related]

  • 4. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.
    J Neurooncol; 2011 Nov 25; 105(2):345-57. PubMed ID: 21643842
    [Abstract] [Full Text] [Related]

  • 5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 6. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.
    Mod Pathol; 2013 Jul 17; 26(7):922-9. PubMed ID: 23429602
    [Abstract] [Full Text] [Related]

  • 7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.
    Pathol Res Pract; 2018 Jun 17; 214(6):881-888. PubMed ID: 29650441
    [Abstract] [Full Text] [Related]

  • 8. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL, Lee L, See AAQ, Ang TY, Ang BT, King NKK.
    BMC Cancer; 2020 Jan 31; 20(1):79. PubMed ID: 32005184
    [Abstract] [Full Text] [Related]

  • 9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.
    Tumour Biol; 2016 Oct 31; 37(10):13571-13579. PubMed ID: 27468718
    [Abstract] [Full Text] [Related]

  • 10. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.
    Neurosurgery; 2010 Dec 31; 67(6):1681-91. PubMed ID: 21107199
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP.
    Asian Pac J Cancer Prev; 2014 Dec 31; 15(24):10893-8. PubMed ID: 25605197
    [Abstract] [Full Text] [Related]

  • 12. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.
    Clin Cancer Res; 2010 Mar 01; 16(5):1597-604. PubMed ID: 20160062
    [Abstract] [Full Text] [Related]

  • 13. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
    Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F.
    Childs Nerv Syst; 2010 Aug 01; 26(8):1051-6. PubMed ID: 20552207
    [Abstract] [Full Text] [Related]

  • 14. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
    Siegal T.
    Adv Tech Stand Neurosurg; 2016 Aug 01; (43):91-108. PubMed ID: 26508407
    [Abstract] [Full Text] [Related]

  • 15. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
    Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.
    PLoS One; 2011 Aug 01; 6(8):e23332. PubMed ID: 21829728
    [Abstract] [Full Text] [Related]

  • 16. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A.
    Neuro Oncol; 2017 Mar 01; 19(3):394-404. PubMed ID: 27571882
    [Abstract] [Full Text] [Related]

  • 17. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L.
    J Neurooncol; 2011 Jun 01; 103(2):343-51. PubMed ID: 20857319
    [Abstract] [Full Text] [Related]

  • 18. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M, German Glioma Network.
    Clin Cancer Res; 2013 Sep 15; 19(18):5146-57. PubMed ID: 23918605
    [Abstract] [Full Text] [Related]

  • 19. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.
    AJNR Am J Neuroradiol; 2012 Aug 15; 33(7):1349-55. PubMed ID: 22322613
    [Abstract] [Full Text] [Related]

  • 20. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.
    Gene; 2015 Jan 01; 554(1):81-6. PubMed ID: 25455102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.